INCY News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IN

Mkt Cap

$22.93B

Volume

1.02M

Next Earnings

October 27th

Loading chart

IN

INCYIncyte Genomics Inc

INCY

Pay with—

Available Balance0.00

IN

Mkt Cap

$22.96B

Volume

1.02M

Next Earnings

October 27th

Chart Financials Earnings News About Insider Filings

INCY or TECH: Which Is the Better Value Stock Right Now?A comparison of two medical-biomedical and genetics stocks reveals that Incyte (INCY) is the more attractive value investment option. INCY holds a Zacks Rank #2 (Buy) with improving earnings outlook and a Value grade of B, while Techne (TECH) has a Zacks Rank #3 (Hold) and Value grade of D. INCY's lower PEG ratio (2.67 vs 7.53) and P/B ratio (3.94 vs 5.38) suggest better valuation metrics.Zacks Investment Research · Sep 30, 2026

Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster PotentialIncyte Corporation agreed to acquire Vega Therapeutics for $1.25 billion upfront to add VGA039, a late-stage monoclonal antibody candidate for von Willebrand disease, to its hematology portfolio. The deal could reach $2 billion with milestone payments. VGA039, in Phase 3 development, has potential to become the first subcutaneous prophylactic treatment for VWD and analysts project blockbuster commercial potential with over $1 billion market opportunity.Benzinga · Jun 9, 2026

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD IndicationCMS reported successful phase 3 clinical trial results for ruxolitinib cream in treating mild to moderate atopic dermatitis, with significantly higher patient improvement rates compared to placebo and minimal adverse events.GlobeNewswire Inc. · Sep 28, 2025

Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsightThe liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. The pipeline features 15+ companies and 20+ therapies in various stages of development.GlobeNewswire Inc. · May 27, 2025

Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activitésMerus reported positive interim data from its Phase II trial of petosemtamab in combination with pembrolizumab for first-line treatment of recurrent/metastatic HNSCC expressing PD-L1. The company also provided updates on its ongoing Phase III trials for petosemtamab and its collaboration programs.GlobeNewswire Inc. · May 9, 2025

Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable TreatmentsThe global generic oncology drugs market is expected to grow from $24.39 billion in 2025 to $30.99 billion by 2034, driven by rising cancer rates and demand for affordable treatments. The market is dominated by North America and is projected to see the fastest growth in Asia Pacific.GlobeNewswire Inc. · May 7, 2025

Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth MarketThe atopic dermatitis drugs market is projected to reach $31 billion by 2034, driven by the rising prevalence of the condition, advancements in biologic therapies, and growing awareness. The biologics segment led the market in 2024, with new biologic injections targeting inflammatory pathways expanding treatment options.GlobeNewswire Inc. · Apr 18, 2025

Why Incyte Stock Was Tanking This WeekIncyte's investigational drug povorcitinib met its primary endpoint in two phase 3 trials for treating moderate to severe hidradenitis suppurativa, but some analysts were expecting better results given the drug's performance in phase 2 trials. The drug will face competition from UCB's Bimzelx, which is already approved by the FDA.The Motley Fool · Mar 21, 2025

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm LumpsIncyte reported mixed results from its late-stage Opzelura studies in prurigo nodularis, a skin condition with itchy firm lumps. The TRuE-PN1 study met its primary endpoint, but the TRuE-PN2 study missed statistical significance due to a high placebo response.Benzinga · Mar 10, 2025

Immunotherapy in Oncology Patent Landscape Report and Forecast 2024-2032: Identify Emerging Therapeutic Targets and Assess the Competitive LandscapeThe immunotherapy in oncology market is projected to grow at a CAGR of 11.6%, reaching USD 319.5 billion by 2032. The patent landscape analysis report examines the dynamic interplay between innovation and industry growth, identifying emerging therapeutic targets and assessing the competitive landscape.GlobeNewswire Inc. · Mar 6, 2025

to start trading

IN

INCYIncyte Genomics Inc

INCY

Pay with—

Available Balance0.00

Your PositionYou don't own any INCY yet.

Related Tickers

Earnings